CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie,John B G Mackey,Thomas Jamieson,Erik Ramon-Gil,Thomas M Drake,Frédéric Fercoq,William Clark,Kathryn Gilroy,Ann Hedley,Colin Nixon,Saimir Luli,Maja Laszczewska,Roser Pinyol,Roger Esteban-Fabró,Catherine E Willoughby,Philipp K Haber,Carmen Andreu-Oller,Mohammad Rahbari,Chaofan Fan,Dominik Pfister,Shreya Raman,Niall Wilson,Miryam Müller,Amy Collins,Daniel Geh,Andrew Fuller,David McDonald,Gillian Hulme,Andrew Filby,Xabier Cortes-Lavaud,Noha-Ehssan Mohamed,Catriona A Ford,Ximena L Raffo Iraolagoitia,Amanda J McFarlane,Misti V McCain,Rachel A Ridgway,Edward W Roberts,Simon T Barry,Gerard J Graham,Mathias Heikenwälder,Helen L Reeves,Josep M Llovet,Leo M Carlin,Thomas G Bird,Owen J Sansom,Derek A Mann
DOI: https://doi.org/10.1136/gutjnl-2021-326259
IF: 24.5
2022-09-08
Gut
Abstract:Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy. Design Neutrophil infiltration was characterised in human HCC and mouse models of HCC. Late-stage intervention with anti-PD1 and/or a CXCR2 inhibitor was performed in murine models of NASH-HCC. The tumour immune microenvironment was characterised by imaging mass cytometry, RNA-seq and flow cytometry. Results Neutrophils expressing CXCR2, a receptor crucial to neutrophil recruitment in acute-injury, are highly represented in human NASH-HCC. In models of NASH-HCC lacking response to ICI, the combination of a CXCR2 antagonist with anti-PD1 suppressed tumour burden and extended survival. Combination therapy increased intratumoural XCR1 + dendritic cell activation and CD8 + T cell numbers which are associated with anti-tumoural immunity, this was confirmed by loss of therapeutic effect on genetic impairment of myeloid cell recruitment, neutralisation of the XCR1-ligand XCL1 or depletion of CD8 + T cells. Therapeutic benefit was accompanied by an unexpected increase in tumour-associated neutrophils (TANs) which switched from a protumour to anti-tumour progenitor-like neutrophil phenotype. Reprogrammed TANs were found in direct contact with CD8 + T cells in clusters that were enriched for the cytotoxic anti-tumoural protease granzyme B. Neutrophil reprogramming was not observed in the circulation indicative of the combination therapy selectively influencing TANs. Conclusion CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.
gastroenterology & hepatology